CHRS
Coherus Oncology, Inc.
Biotechnology
Market Cap$212M
5Y Perf.-90.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CHRS vs AMRX
Revenue, margins, valuation, and 5-year total return — side by side.
AMRX
Amneal Pharmaceuticals, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$4.28B
5Y Perf.+179.7%
CHRS vs AMRX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CHRS | AMRX |
|---|---|---|
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
| Market Cap | $212M | $4.28B |
| Revenue (TTM) | $42M | $3.02B |
| Net Income (TTM) | $168M | $72M |
| Gross Margin | -37.3% | 36.9% |
| Operating Margin | -429.5% | -0.2% |
| Forward P/E | 1.2x | 13.7x |
| Total Debt | $1M | $124M |
| Cash & Equiv. | $89M | $282M |
CHRS vs AMRX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CHRS
AMRX
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Coherus Oncology, I… (CHRS) | 100 | 9.4 | -90.6% |
| Amneal Pharmaceutic… (AMRX) | 100 | 279.7 | +179.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CHRS vs AMRX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CHRS and AMRX are tied at the top with 3 categories each — the right choice depends on your priorities. Amneal Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
CHRS
Coherus Oncology, Inc.
The Value Play
CHRS has the current edge in this matchup, primarily because of its strength in value and quality.
- Lower P/E (1.2x vs 13.7x)
- 398.4% margin vs AMRX's 2.4%
- 42.4% ROA vs AMRX's 2.0%
Best for: value and quality
AMRX
Amneal Pharmaceuticals, Inc.
The Income Pick
AMRX is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.17
- Rev growth 8.0%, EPS growth 157.9%, 3Y rev CAGR 10.9%
- -54.3% 10Y total return vs CHRS's -90.9%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AMRX | 8.0% revenue growth vs CHRS's -84.2% |
| Value | CHRS | Lower P/E (1.2x vs 13.7x) |
| Quality / Margins | CHRS | 398.4% margin vs AMRX's 2.4% |
| Stability / Safety | AMRX | Beta 1.17 vs CHRS's 2.29 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | AMRX | +89.7% vs CHRS's +88.2% |
| Efficiency (ROA) | CHRS | 42.4% ROA vs AMRX's 2.0% |
CHRS vs AMRX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
CHRS vs AMRX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAMRXLAGGINGCHRS
CHRSCoherus Oncology, Inc.
1leads
AMRXAmneal Pharmaceutical…
3leads
6 Total Categories
CATEGORYLEADERvs CHRSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AMRX5/6
Valuation MetricsMultiples, price ratios, and targets
CHRS2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
AMRX5/6
Risk & VolatilityBeta, volatility, and downside exposure
AMRX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
AMRX leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMRX is the larger business by revenue, generating $3.0B annually — 71.6x CHRS's $42M. Profitability is closely matched — net margins range from 4.0% (CHRS) to 2.4% (AMRX). On growth, AMRX holds the edge at +11.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CHRSCoherus Oncology,… | AMRXAmneal Pharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $42M | $3.0B |
| EBITDAEarnings before interest/tax | -$184M | $169M |
| Net IncomeAfter-tax profit | $168M | $72M |
| Free Cash FlowCash after capex | -$139M | $150M |
| Gross MarginGross profit ÷ Revenue | -37.3% | +36.9% |
| Operating MarginEBIT ÷ Revenue | -4.3% | -0.2% |
| Net MarginNet income ÷ Revenue | +4.0% | +2.4% |
| FCF MarginFCF ÷ Revenue | -3.3% | +5.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -76.5% | +11.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +29.5% | +2.1% |
AMRX leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
CHRS leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
At 1.2x trailing earnings, CHRS trades at a 98% valuation discount to AMRX's 61.9x P/E.
| Metric | CHRSCoherus Oncology,… | AMRXAmneal Pharmaceut… |
|---|---|---|
| Market CapShares × price | $212M | $4.3B |
| Enterprise ValueMkt cap + debt − cash | $125M | $4.1B |
| Trailing P/EPrice ÷ TTM EPS | 1.22x | 61.91x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.71x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5.03x | 1.42x |
| Price / BookPrice ÷ Book value/share | 3.45x | 4.58x |
| Price / FCFMarket cap ÷ FCF | — | 15.86x |
CHRS leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — CHRS and AMRX each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
CHRS delivers a 7.9% return on equity — every $100 of shareholder capital generates $8 in annual profit, vs $7 for AMRX. CHRS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMRX's 0.13x. On the Piotroski fundamental quality scale (0–9), AMRX scores 8/9 vs CHRS's 4/9, reflecting strong financial health.
| Metric | CHRSCoherus Oncology,… | AMRXAmneal Pharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | +7.9% | +7.5% |
| ROA (TTM)Return on assets | +42.4% | +2.0% |
| ROICReturn on invested capital | — | -0.2% |
| ROCEReturn on capital employed | -127.8% | -0.2% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 8 |
| Debt / EquityFinancial leverage | 0.02x | 0.13x |
| Net DebtTotal debt minus cash | -$87M | -$158M |
| Cash & Equiv.Liquid assets | $89M | $282M |
| Total DebtShort + long-term debt | $1M | $124M |
| Interest CoverageEBIT ÷ Interest expense | -28.88x | 2.09x |
Evenly matched — CHRS and AMRX each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
AMRX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AMRX five years ago would be worth $23,564 today (with dividends reinvested), compared to $1,207 for CHRS. Over the past 12 months, AMRX leads with a +89.7% total return vs CHRS's +88.2%. The 3-year compound annual growth rate (CAGR) favors AMRX at 88.9% vs CHRS's -40.1% — a key indicator of consistent wealth creation.
| Metric | CHRSCoherus Oncology,… | AMRXAmneal Pharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | +27.7% | +7.6% |
| 1-Year ReturnPast 12 months | +88.2% | +89.7% |
| 3-Year ReturnCumulative with dividends | -78.5% | +574.3% |
| 5-Year ReturnCumulative with dividends | -87.9% | +135.6% |
| 10-Year ReturnCumulative with dividends | -90.9% | -54.3% |
| CAGR (3Y)Annualised 3-year return | -40.1% | +88.9% |
AMRX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
AMRX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
AMRX is the less volatile stock with a 1.17 beta — it tends to amplify market swings less than CHRS's 2.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMRX currently trades 89.6% from its 52-week high vs CHRS's 66.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CHRSCoherus Oncology,… | AMRXAmneal Pharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.29x | 1.17x |
| 52-Week HighHighest price in past year | $2.62 | $15.20 |
| 52-Week LowLowest price in past year | $0.71 | $7.02 |
| % of 52W HighCurrent price vs 52-week peak | +66.9% | +89.6% |
| RSI (14)Momentum oscillator 0–100 | 51.3 | 59.9 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 1.7M |
AMRX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CHRS as "Buy" and AMRX as "Buy". Consensus price targets imply 244.0% upside for CHRS (target: $6) vs 24.8% for AMRX (target: $17).
| Metric | CHRSCoherus Oncology,… | AMRXAmneal Pharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $6.02 | $17.00 |
| # AnalystsCovering analysts | 16 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AMRX leads in 3 of 6 categories (Income & Cash Flow, Total Returns). CHRS leads in 1 (Valuation Metrics). 1 tied.
Best OverallAmneal Pharmaceuticals, Inc. (AMRX)Leads 3 of 6 categories
Loading custom metrics...
CHRS vs AMRX: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CHRS or AMRX a better buy right now?
For growth investors, Amneal Pharmaceuticals, Inc.
(AMRX) is the stronger pick with 8. 0% revenue growth year-over-year, versus -84. 2% for Coherus Oncology, Inc. (CHRS). Coherus Oncology, Inc. (CHRS) offers the better valuation at 1. 2x trailing P/E, making it the more compelling value choice. Analysts rate Coherus Oncology, Inc. (CHRS) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CHRS or AMRX?
On trailing P/E, Coherus Oncology, Inc.
(CHRS) is the cheapest at 1. 2x versus Amneal Pharmaceuticals, Inc. at 61. 9x.
03Which is the better long-term investment — CHRS or AMRX?
Over the past 5 years, Amneal Pharmaceuticals, Inc.
(AMRX) delivered a total return of +135. 6%, compared to -87. 9% for Coherus Oncology, Inc. (CHRS). Over 10 years, the gap is even starker: AMRX returned -54. 3% versus CHRS's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CHRS or AMRX?
By beta (market sensitivity over 5 years), Amneal Pharmaceuticals, Inc.
(AMRX) is the lower-risk stock at 1. 17β versus Coherus Oncology, Inc. 's 2. 29β — meaning CHRS is approximately 95% more volatile than AMRX relative to the S&P 500. On balance sheet safety, Coherus Oncology, Inc. (CHRS) carries a lower debt/equity ratio of 2% versus 13% for Amneal Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CHRS or AMRX?
By revenue growth (latest reported year), Amneal Pharmaceuticals, Inc.
(AMRX) is pulling ahead at 8. 0% versus -84. 2% for Coherus Oncology, Inc. (CHRS). On earnings-per-share growth, the picture is similar: Coherus Oncology, Inc. grew EPS 472. 0% year-over-year, compared to 157. 9% for Amneal Pharmaceuticals, Inc.. Over a 3-year CAGR, AMRX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CHRS or AMRX?
Coherus Oncology, Inc.
(CHRS) is the more profitable company, earning 398. 4% net margin versus 2. 4% for Amneal Pharmaceuticals, Inc. — meaning it keeps 398. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMRX leads at -0. 2% versus -429. 5% for CHRS. At the gross margin level — before operating expenses — AMRX leads at 36. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CHRS or AMRX more undervalued right now?
Analyst consensus price targets imply the most upside for CHRS: 244.
0% to $6. 02.
08Which pays a better dividend — CHRS or AMRX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is CHRS or AMRX better for a retirement portfolio?
For long-horizon retirement investors, Amneal Pharmaceuticals, Inc.
(AMRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17)). Coherus Oncology, Inc. (CHRS) carries a higher beta of 2. 29 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMRX: -54. 3%, CHRS: -90. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CHRS and AMRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CHRS is a small-cap deep-value stock; AMRX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(CHRS: -76.5% · AMRX: 11.5%)Net Margin>
%
(CHRS: 398.4% · AMRX: 2.4%)P/E Ratio<
x
(CHRS: 1.2x · AMRX: 61.9x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.